Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
The Israel Medical Association Journal : IMAJ|May 20, 2014
Outcome differences in patients with precursor B cell acute lymphocytic leukemia over time: a retrospective analysisArie Apel, Meirav Kedmi, Etai Levi, et al.
American Journal of Hematology|June 29, 2021
BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignanciesKatrin Herzog Tzarfati, Odit Gutwein, Arie Apel, et al.
Annals of Hematology|June 22, 2022
Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysisOfir Wolach, Avraham Frisch, Liat Shargian, et al.
Annals of Hematology|September 13, 2019
Midostaurin in combination with intensive chemotherapy is safe and associated with improved remission rates and higher transplantation rates in first remission-a multi-center historical control studyTamar Berger, Uri Rozovski, Yakir Moshe, et al.
American Journal of Hematology|April 9, 2021
Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practiceArie Apel, Yakir Moshe, Yishai Ofran, et al.
American Journal of Hematology|June 21, 2017
Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioningAvichai Shimoni, Luca Vago, Massimo Bernardi, et al.
Molecular Cancer Therapeutics|July 22, 2017
Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell LymphomaSalvia Jain, Abigail Washington, Rebecca Karp Leaf, et al.
Leukemia & Lymphoma|May 19, 2020
Venetoclax is safe and efficacious in relapsed/refractory AMLChezi Ganzel, Ron Ram, Alexander Gural, et al.
Transplantation and Cellular Therapy|July 2, 2021
Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort StudyRon Ram, David Hagin, Nino Kikozashvilli, et al.
British Journal of Haematology|January 21, 2017
Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1Michal Bar-Natan, Dina Stroopinsky, Katarina Luptakova, et al.
Pageof 3